In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biofrontera Pharma grosses $11.5mm in private placement

Executive Summary

Biofrontera Pharmaceuticals (drug discovery for nervous system disorders. Alzheimer's and Parkinson's diseases, and schizophrenia) grossed $11.5mm (DM23mm) in an oversubscribed private placement led by 3i Group Investments, which was joined by Alta Vista Equity Partner GMBH, TRE Holding, and Technologie BG der Deutschen Ausgleichsbank. Investors in the company's first round of financing, LeVenture KB and TechnoMedia KB, also participated.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies